HISHOH Biopharma Inc. (Headquarters: Chuo-ku, Tokyo; President and CEO: Joji Hayashida; hereinafter "the Company"), which is working on the development of next-generation allergy immunotherapy with the vision of "Toward a world without allergies," is pleased to announce that the Company's project, "Development of a novel sublingual immunotherapy using a next-generation TLR4 agonist, HSO-001, for house dust mite allergic rhinitis," has been selected for the FY2026 "Drug Discovery Venture Ecosystem Enhancement Project (Drug Discovery Venture Public Call)" (13th round) implemented by the Japan Agency for Medical Research and Development (hereinafter "AMED").
AMED Website:https://www.amed.go.jp/koubo/03008/01/C_00009.html
This project involves AMED certifying venture capitals (hereinafter "VCs") that provide hands-on, drug discovery-focused commercialization support. Requiring investment from these certified VCs, the project actively supports drug discovery ventures in their practical application and development, particularly those aiming for commercialization in overseas markets in addition to Japan.
With the support provided by this project, we will promote the global development of HSO-001, including Phase 1 and Phase 2 clinical trials, and aim to contribute to patients worldwide.
That's all.
[Contact Information for Inquiries Regarding This Matter]
HISHOH Biopharma Co.
Email: mail@hishoh.jp
TEL: 03-6202-7541
Comments